Pancancer-Somatic-PGx

A computational tool that characterizes the landscape of somatic loss-of-function variants in key pharmacogenes (CYP2D6, CYP2C19, DPYD, TPMT) across multiple TCGA tumour types. It models how tumour-acquired somatic mutations affect drug metabolism phenotypes, complementing germline analysis.